• ISSN 16748301
  • CN 32-1810/R
Article Contents

Citation:

Macrophage-derived matrix metalloproteinase-1 enhances aortic aneurysm formation in transgenic rabbits

  • Increased expression of matrix metalloproteinase-1 (MMP-1) has been observed in the lesions of atherosclerosis and aneurysms; however, it is not fully understood whether macrophage-derived MMP-1 affects these diseases. To investigate whether macrophage-derived MMP-1 participates in the development of vascular diseases, we generated transgenic (Tg) rabbits expressing human MMP-1 in the monocyte/macrophage lineage under the control of the human scavenger receptor enhancer/promoter. Tg rabbits exhibited no visible abnormalities throughout their bodies. Western blotting analysis revealed that the amount of MMP-1 proteins in the conditioned media secreted from peritoneal macrophages of Tg rabbits was up to 3-fold higher than that in non-Tg rabbits. For the first experiment, Tg and non-Tg rabbits were fed a cholesterol diet for 16 weeks, and aortic and coronary atherosclerosis were evaluated. The gross lesion area of aortic atherosclerosis in Tg rabbits was not significantly different from that in non-Tg rabbits, but Tg rabbits had marked destruction of the medial elastic lamina of the aortic lesions on microscopic examination. For the second experiment, we generated aortic aneurysms by incubating with elastase. Compared with non-Tg rabbits, Tg rabbits exhibited a significantly greater aortic dilation. Increased macrophage-derived MMP-1 led to increased medial destruction in both aortic atherosclerosis and aneurysms. These results demonstrate that MMP-1 plays a different role in the pathogenesis of atherosclerosis and aneurysms.
  • 加载中
  • [1] Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis[J]. J Atheroscler Thromb, 2003, 10(2): 63–71 doi: 10.5551/jat.10.63
    [2] Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis[J]. Cell, 2011, 145(3): 341–355 doi: 10.1016/j.cell.2011.04.005
    [3] Libby P. Inflammation in atherosclerosis[J]. Nature, 2002, 420(6917): 868–874 doi: 10.1038/nature01323
    [4] Tabas I, Bornfeldt KE. Macrophage phenotype and function in different stages of atherosclerosis[J]. Circ Res, 2016, 118(4): 653–667 doi: 10.1161/CIRCRESAHA.115.306256
    [5] Dollery CM, Libby P. Atherosclerosis and proteinase activation[J]. Cardiovasc Res, 2006, 69(3): 625–635 doi: 10.1016/j.cardiores.2005.11.003
    [6] Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability[J]. Arterioscler Thromb Vasc Biol, 2008, 28(12): 2108–2114 doi: 10.1161/ATVBAHA.108.173898
    [7] Galis ZS, Sukhova GK, Kranzhöfer R, et al. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases[J]. Proc Natl Acad Sci U S A, 1995, 92(2): 402–406 doi: 10.1073/pnas.92.2.402
    [8] Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques[J]. J Clin Invest, 1994, 94(6): 2493–2503 doi: 10.1172/JCI117619
    [9] Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly[J]. Circ Res, 2002, 90(3): 251–262 doi: 10.1161/res.90.3.251
    [10] Newby AC. Matrix metalloproteinase inhibition therapy for vascular diseases[J]. Vascul Pharmacol, 2012, 56(5-6): 232–244 doi: 10.1016/j.vph.2012.01.007
    [11] Sinha S, Frishman WH. Matrix metalloproteinases and abdominal aortic aneurysms: a potential therapeutic target[J]. J Clin Pharmacol, 1998, 38(12): 1077–1088
    [12] Wang Z, Zhang J, Li H, et al. Hyperlipidemia-associated gene variations and expression patterns revealed by whole-genome and transcriptome sequencing of rabbit models[J]. Sci Rep, 2016, 6(1): 26942 doi: 10.1038/srep26942
    [13] Yu Y, Koike T, Kitajima S, et al. Temporal and quantitative analysis of expression of metalloproteinases (MMPs) and their endogenous inhibitors in atherosclerotic lesions[J]. Histol Histopathol, 2008, 23(12): 1503–1516
    [14] Pardo A, Selman M. MMP-1: the elder of the family[J]. Int J Biochem Cell Biol, 2005, 37(2): 283–288 doi: 10.1016/j.biocel.2004.06.017
    [15] Nikkari ST, Geary RL, Hatsukami T, et al. Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinases-1 in restenosis after carotid endarterectomy[J]. Am J Pathol, 1996, 148(3): 777–783
    [16] Sukhova GK, Schönbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques[J]. Circulation, 1999, 99(19): 2503–2509 doi: 10.1161/01.CIR.99.19.2503
    [17] Ye S, Gale CR, Martyn CN. Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease[J]. Eur Heart J, 2003, 24(18): 1668–1671 doi: 10.1016/S0195-668X(03)00385-3
    [18] Pearce E, Tregouet DA, Samnegård A, et al. Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction[J]. Circ Res, 2005, 97(10): 1070–1076 doi: 10.1161/01.RES.0000189302.03303.11
    [19] Irizarry E, Newman KM, Gandhi RH, et al. Demonstration of interstitial collagenase in abdominal aortic aneurysm disease[J]. J Surg Res, 1993, 54(6): 571–574 doi: 10.1006/jsre.1993.1087
    [20] Knox JB, Sukhova GK, Whittemore AD, et al. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases[J]. Circulation, 1997, 95(1): 205–212 doi: 10.1161/01.CIR.95.1.205
    [21] Vincenti MP, Coon CI, Mengshol JA, et al. Cloning of the gene for interstitial collagenase-3 (matrix metalloproteinase-13) from rabbit synovial fibroblasts: differential expression with collagenase-1 (matrix metalloproteinase-1)[J]. Biochem J, 1998, 331(Pt 1): 341–346
    [22] Lemaître V, O’Byrne TK, Borczuk AC, et al. ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis[J]. J Clin Invest, 2001, 107(10): 1227–1234 doi: 10.1172/JCI9626
    [23] Fan J, Kitajima S, Watanabe T, et al. Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine[J]. Pharmacol Ther, 2015, 146: 104–119 doi: 10.1016/j.pharmthera.2014.09.009
    [24] Fan J, Watanabe T. Transgenic rabbits as therapeutic protein bioreactors and human disease models[J]. Pharmacol Ther, 2003, 99(3): 261–282 doi: 10.1016/S0163-7258(03)00069-X
    [25] Fan J, Wang X, Wu L, et al. Macrophage-specific overexpression of human matrix metalloproteinase-12 in transgenic rabbits[J]. Transgenic Res, 2004, 13(3): 261–269 doi: 10.1023/B:TRAG.0000034717.70729.61
    [26] Recillas-Targa F, Pikaart MJ, Burgess-Beusse B, et al. Position-effect protection and enhancer blocking by the chicken beta-globin insulator are separable activities[J]. Proc Natl Acad Sci U S A, 2002, 99(10): 6883–6888 doi: 10.1073/pnas.102179399
    [27] Koike T, Kitajima S, Yu Y, et al. Human C-reactive protein does not promote atherosclerosis in transgenic rabbits[J]. Circulation, 2009, 120(21): 2088–2094 doi: 10.1161/CIRCULATIONAHA.109.872796
    [28] Zhang J, Niimi M, Yang D, et al. Deficiency of cho